Importer of Controlled Substances Application: Cody Laboratories, Inc., 50032 [2015-20278]
Download as PDF
<![CDATA[
50032
Federal Register / Vol. 80, No. 159 / Tuesday, August 18, 2015 / Notices
Kamal Tiwari, 76 FR 71604, 71606
(2011) (citing cases).
Here, the evidence shows that
Registrant’s medical license has been
suspended by the Texas Medical Board.
I therefore hold that Registrant no longer
holds authority under the laws of Texas,
the State in which he is registered, to
dispense controlled substances and that
therefore, he is not entitled to maintain
his DEA registration. See 21 U.S.C.
802(21), 823(f), 824(a)(3). Accordingly, I
will order that his registration be
revoked.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(f) and 824(a), as well
as 28 CFR 0.100(b), I order that DEA
Certificate of Registration FG1729699
issued to Ronald A. Green, M.D., be, and
it hereby is, revoked. I further order that
any application of Ronald A. Green,
M.D., to renew or modify his
registration, be, and it hereby is, denied.
This Order is effective immediately.3
Dated: August 10, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015–20349 Filed 8–17–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152. Comments
and request for hearing on applications
to import narcotic raw material are not
appropriate. 72 FR 3417 (January 25,
2007).
DEPARTMENT OF JUSTICE
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on May 8,
2015, Cody Laboratories, Inc., 601
Yellowstone Avenue, Steve Hartman,
Vice President of Compliance, Cody,
Wyoming 82414–9321 applied to be
registered as an importer of the
following basic classes of controlled
substances:
On July 15, 2014, the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration (DEA), issued an Order
to Show Cause to Nicholas J. Nardacci,
M.D. (Respondent), of Albuquerque,
New Mexico. The Show Cause Order
proposed the revocation of
Respondent’s DEA Certificate of
Registration AN9444592, on the ground
that he lacks authority to handle
controlled substances in New Mexico,
the State in which he is registered with
DEA. Show Cause Order, at 1 (citing 21
U.S.C. 823(f) & 824(a)(3)).
The Show Cause Order specifically
alleged that on August 20, 2013, the
New Mexico Medical Board (the Board)
issued a Decision and Order suspending
Respondent’s medical license, based on
its finding that since 2010, Respondent
had prescribed medical marijuana for
numerous persons by certifying to the
New Mexico Department of Health that
he was each person’s medical provider,
without first establishing that he was
the primary caregiver for any of those
persons or otherwise first establishing a
physician-patient relationship as
required under NMSA §§ 26–2B–1 et
seq. Id. at 1. Based on the State’s
suspension of his medical license, the
Order alleged that Respondent was
without authority to handle controlled
substances in New Mexico, the State in
which he is registered with DEA, and
thus, he is not entitled to maintain his
registration. Id. (citing 21 U.S.C.
801(21), 823(f) and 824(a)(3)).1
On or about August 4, 2014, the Show
Cause Order was served on Respondent,
and on September 2, 2014, Respondent
filed a letter with the Office of
Administrative Law Judges. GX 4.
Therein, Respondent acknowledged that
he had been served with the Show
Cause Order and requested additional
time in which to respond to the Order
so that he could retain a lawyer;
however, he did not request a hearing.
Id. Respondent also asserted that on
August 12, 2014, the Board had issued
a Return to Work Order and therefore,
his state medical license was now
active. Id. The matter was then assigned
SUPPLEMENTARY INFORMATION:
Importer of Controlled Substances
Application: Cody Laboratories, Inc.
ACTION:
Controlled substance
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
or before September 17, 2015. Such
persons may also file a written request
for a hearing on the application
pursuant to 21 CFR 1301.43 on or before
September 17, 2015.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODXL, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
asabaliauskas on DSK5VPTVN1PROD with NOTICES
DATES:
3 Based on the findings of fact and conclusions of
law which led the TMB to concluded that
Registrant’s ‘‘continuation in the practice of
medicine would constitute a continuing threat to
public welfare,’’ GX 3, at 3; I conclude that the
public interest requires that this Order be effective
immediately. See 21 CFR 1316.67.
VerDate Sep<11>2014
17:02 Aug 17, 2015
Jkt 235001
Phenylacetone (8501) ..................
Poppy Straw Concentrate (9670)
Tapentadol (9780) ........................
Schedule
II
II
II
The company plans to import narcotic
raw materials for manufacturing and
further distribution to its customers.
The company is registered with the DEA
as a manufacturer of several controlled
substances that are manufactured from
poppy straw concentrate.
The company plans to import an
intermediate form of tapentadol (9780),
to bulk manufacturer tapentadol for
distribution to its customers.
Dated: August 10, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–20278 Filed 8–17–15; 8:45 am]
Drug Enforcement Administration
[Docket No. 14–24]
Nicholas Nardacci, M.D.; Decision and
Order
BILLING CODE 4410–09–P
PO 00000
1 The Show Cause Order also notified Respondent
of his right to request a hearing on the allegations,
or to submit a written statement in lieu of a hearing,
the procedure for electing either option, and the
consequence for failing to elect either option. Show
Cause Order, at 2 (citing 21 CFR 1301.43).
Frm 00048
Fmt 4703
Sfmt 4703
E:\FR\FM\18AUN1.SGM
18AUN1
]]>Agencies
[Federal Register Volume 80, Number 159 (Tuesday, August 18, 2015)]
[Notices]
[Page 50032]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-20278]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Cody Laboratories,
Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.34(a) on or before September 17, 2015. Such persons may also file
a written request for a hearing on the application pursuant to 21 CFR
1301.43 on or before September 17, 2015.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODXL,
8701 Morrissette Drive, Springfield, Virginia 22152. Request for
hearings should be sent to: Drug Enforcement Administration, Attention:
Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.
Comments and request for hearing on applications to import narcotic raw
material are not appropriate. 72 FR 3417 (January 25, 2007).
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Deputy Assistant Administrator of the DEA Office of Diversion
Control (``Deputy Assistant Administrator'') pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on May 8,
2015, Cody Laboratories, Inc., 601 Yellowstone Avenue, Steve Hartman,
Vice President of Compliance, Cody, Wyoming 82414-9321 applied to be
registered as an importer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Phenylacetone (8501)....................... II
Poppy Straw Concentrate (9670)............. II
Tapentadol (9780).......................... II
------------------------------------------------------------------------
The company plans to import narcotic raw materials for
manufacturing and further distribution to its customers. The company is
registered with the DEA as a manufacturer of several controlled
substances that are manufactured from poppy straw concentrate.
The company plans to import an intermediate form of tapentadol
(9780), to bulk manufacturer tapentadol for distribution to its
customers.
Dated: August 10, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-20278 Filed 8-17-15; 8:45 am]
BILLING CODE 4410-09-P
